Combining High-frequency Micro-ultrasound and Multiparametric MRI Target Biopsy for Detecting Prostate Cancer
Recruiting now · Not applicable
Conditions studied: Prostatic Neoplasm of Uncertain Behavior
In brief
\*\*Study Goal:\*\* The purpose of this clinical trial is to determine if combining high-frequency micro-ultrasound with multiparametric MRI biopsy and a systematic biopsy can better detect clinically significant prostate cancer compared to current standard methods. This study is aimed at men who may have prostate cancer. \*\*Main Questions the Study Aims to Answer:\*\* 1. Does the combination of new biopsy methods detect more clinically significant prostate cancers than the current standard method? 2. Does the new method not increase the detection of less serious forms of cancer beyond what the standard method detects? \*\*Participation in the Study:\*\* Participants in this study will undergo the following procedures: * A high-frequency micro-ultrasound examination of the prostate. * A multiparametric MRI-targeted biopsy of the prostate. * A systematic biopsy of the prostate. \*\*Comparison Group:\*\* Researchers will compare the new combination method with the current standard method to see if the new approach is more effective. \*\*Participants will:\*\* * Undergo several exams and biopsies depending on the results of previous tests. * Attend regular follow-up appointments to monitor potential side effects and evaluate prostate health. * Record their experiences and any symptoms in a diary.
Key facts
- Study ID
- NCT06579911
- Run by
- Salzburger Landeskliniken
- People needed
- 400
- Starts
- 2023-11-01
- Expected to finish
- 2028-01-01
- Last updated by the study team
- 2026-06-09
Who can join
Age: 18 and older, up to 99. Sex: male. Healthy volunteers: accepted.
You may qualify if…
- Men with suspected clinically significant prostate cancer, identified by the rise in PSA level, suspicious digital rectal examination or both and pathologic multiparametric MRI of the prostate (>= PI-RADS III)
You may not qualify if…
- Patients with histopathologic proven prostate cancer
- PSA > 20 ng/ml
- Finding in digital rectal examination >= cT2c
- Untreated bacterial infection of the prostate
- Untreated coagulopathy
Where it is running
- Uniklinikum Salzburg, Department for Urology and Andrology — Salzburg, State of Salzburg, Austria (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.